Showing results (701-710 of 977) with videos related to

Sort By:
Pageof 98
NPJ Breast Cancer|December 1, 2025
Intrinsic RB activation induces tumoral and stromal anti-tumor responses that limit triple-negative breast cancerYin Wan, Jianxin Wang, Thomas N O'Connor, et al.
NPJ Breast Cancer|November 21, 2025
Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancerLaura A Huppert, Amelia S Gliwa, Madeline Tait, et al.
NPJ Breast Cancer|April 26, 2024
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE studyMatthew P Goetz, Irfan Cicin, Laura Testa, et al.
NPJ Breast Cancer|April 24, 2024
Kataegis in clinical and molecular subgroups of primary breast cancerSrinivas Veerla, Johan Staaf
NPJ Breast Cancer|December 15, 2023
Histopathological growth patterns and tumor-infiltrating lymphocytes in breast cancer liver metastasesSophia Leduc, Maxim De Schepper, François Richard, et al.
NPJ Breast Cancer|December 19, 2023
Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancerSwaathi Jayaraman, Xinyan Wu, Krishna R Kalari, et al.
NPJ Breast Cancer|November 29, 2022
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancerSunil Pancholi, Nikiana Simigdala, Ricardo Ribas, et al.
NPJ Breast Cancer|May 21, 2021
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter studyLinda T Vahdat, Peter Schmid, Andres Forero-Torres, et al.
NPJ Breast Cancer|April 25, 2019
Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiolElla F Jones, Kimberly M Ray, Wen Li, et al.
NPJ Breast Cancer|June 24, 2026
Anlotinib-containing regimens in HR+ advanced breast cancer after prior CDK4/6 inhibitor progressionYifei Chen, Binliang Liu, Zhanhong Chen, et al.
Pageof 98